Jessica Merrill
Senior Editor
Latest From Jessica Merrill
AbbVie’s Ex-Humira Immunology Business Is Booming
The company raised 2024 revenue expectations, driven by the second quarter performance of its Humira successors Skyrizi and Rinvoq.
Pfizer’s Hemophilia A Gene Therapy Superior To Prophylaxis In Phase III
The company’s giroctocogene fitelparvovec, partnered with Sangamo, could compete with BioMarin’s hemophilia A gene therapy Roctavian, but longer-term data may be needed.
Merck & Co.’s Clesrovimab Could Rival Sanofi/AZ’s Beyfortus In RSV
Phase IIb/III trial testing Merck’s prophylactic monoclonal antibody clesrovimab met the primary safety and efficacy endpoints to protect infants from RSV, but the market is competitive.
With Positive Data From Ionis, Angelman Syndrome Race Intensifies
Ionis plans to initiate a Phase III trial for ION582 in the first half of 2025, positioning it just behind Ultragenyx in the race to bring a treatment to market for the rare neurologic condition.
Phathom Voquezna Expansion Strategy Poised To Deliver In GERD
The acid reducer was approved by the US FDA for a substantially larger indication in non-erosive gastroesophageal reflux disease but will have to prove itself commercially against PPIs.
J&J’s Spravato On Track To Be A Blockbuster, Five Years In
Johnson & Johnson’s drug for treatment-resistant depression got off to a slow start when it launched in 2019, but strong sales growth has put it on a blockbuster trajectory this year.